HUMAN INFECTIONS BY SV40: OVERVIEW OF THE EVIDENCE
Although the prevalence of SV40 infections in humans is not known, studies conducted over the last three decades indicate that SV40 infections are occurring in child and adult populations today. These included individuals who received potentially SV40-contaminated vaccines, as well as in persons born after 1963 who could not have been exposed to those vaccines (
5,
11-
14,
17,
18,
25,
26,
28,
40,
46,
49,
55,
62,
63,
66,
67,
71-
74,
76,
78,
86,
88,
89,
92,
94,
95,
102,
104,
111,
115,
117,
120,
124,
125,
129,
130,
132,
133). In addition, 19% of newborn children and 15% of infants 3 to 6 months old at the time of receiving the oral contaminated polio vaccine were shown to excrete infectious SV40 in their stools for up to 5 weeks after vaccination (
75). It is important to point out that the incidence of SV40 infections linked to those vaccines is not known.
SV40 seroprevalence rates in the general populations of the United States and other countries have ranged from 2 to 20% (
13,
78,
95). However, differences in the methodology and low sensitivity of the assays used in some studies make it difficult to ascertain the actual prevalence of SV40 infections. A report by Shah et al. (
99) found that 18% of adult kidney transplant patients had specific neutralizing antibody to SV40. Another study among adult patients showed the presence of SV40 neutralizing antibodies in 16% of human immunodeficiency virus-infected patients and 11% of individuals not infected with human immunodeficiency virus (
49). Among hospitalized children, the overall prevalence of specific SV40 serum neutralizing antibodies was 6% (
12); the SV40 seropositivity among children increased with age (
P = 0.01) and was significantly associated with kidney transplantation (
P < 0.001) (Table
1). Recently, a study of the prevalence of SV40 infections showed rates of 9% in Hungary and 4% in the Czech Republic (
14). Females had a higher rate of SV40 antibodies than males, reaching 16% in Hungary and 8% in the Czech Republic in certain age groups. SV40 infections were found in similar proportions in both countries among persons not exposed to potentially contaminated polio vaccines and in subjects vaccinated in the era of SV40-free vaccines. Minor et al. (
78) recently analyzed over 2,000 sera from the United Kingdom and found an SV40 seroprevalence rate of just under 5%. Most of the neutralizing titers were low, and there was no apparent relationship between antibody positivity and polio vaccine usage. These data suggest that SV40 is being transmitted in the human population today, probably at a relatively low prevalence rate. However, conclusions about seroprevalence rates should be viewed with caution, as very little is known about the human immune response to SV40 infections.
Although the mode of transmission of SV40 among humans is unknown, we speculate that different routes may be involved. Studies with laboratory animals indicate that maternal-infant transmission is one possible route of SV40 spread (
91). This may represent a pathway for SV40 infections in humans (of unknown frequency), as there are reports of the detection and expression of SV40 T-ag and the presence of viral DNA in cases of primary brain cancers in infants and young children (
5,
71,
72,
117,
129,
133). Also, evidence indicates that zoonotic transmission of SV40 should be a consideration in certain populations. Indeed, laboratory workers in contact with SV40-infected monkeys and/or tissues from those animals had a prevalence of antibodies to SV40 in the range of 41 to 55%, suggesting an increased risk for viral infection among this group of workers (
43,
134).
Molecular studies of adult patients with renal disease and recipients of kidney transplants found that SV40 cytopathic effects developed in CV-1 cells cocultured with urinary cells or PBMCs from those patients (
66,
67). SV40 sequences were detected by PCR in kidney biopsies from 56% of patients with focal segmental glomerulosclerosis. SV40 DNA was localized to renal tubular epithelial cell nuclei in renal biopsies of patients with focal segmental glomerulosclerosis as determined by in situ hybridization. In addition, studies showed that SV40 DNA sequences from the viral regulatory region were detected and identified in the allografts of immunocompromised pediatric renal transplant recipients (Fig.
4) and in the native kidney of a young adult lung transplant patient with polyomavirus nephropathy (
11,
12,
77). Different studies have detected SV40 DNA sequences in PBMCs from various patient populations (
26,
31,
66,
72,
73,
132). These results demonstrate the nephrotropic and lymphotropic properties of SV40 and indicate that the kidney can serve as a reservoir for the virus in humans. It appears that patients with acquired and/or iatrogenic immunosuppression are a population at risk for SV40. However, the frequency, natural history, and morbidity of the virus in this increasing patient population are unclear.
Large prospective studies using sensitive and specific reagents for SV40 are needed to determine the prevalence of viral infections in the general population and to define groups of individuals at elevated risk for this emerging pathogen. Similarly important is the need for prospective longitudinal studies that address the morbidity and related mortality of these infections. The use of serologic tests alone may not be the most reliable way to conduct these studies. An enzyme immunoassay method for detection of SV40 antibodies in humans recognizes cross-reactivity between SV40, BKV, and JCV, complicating interpretation of assay results (
126). Similar limitations have been found in serologic methods for identification of human infection with herpes B virus (Cercopithecine herpesvirus 1), which is known also to naturally infect rhesus macaques (
M. mulatta) (
45). Because infection with B virus in humans results in fatal encephalomyelitis or severe neurologic impairment, rapid and conclusive diagnosis is critical in order to control sequelae by this viral pathogen. Serologic assays (including enzyme immunoassay) for B-virus infection in humans are limited by low sensitivity and specificity (
45). Currently, cell culture for the three polyomaviruses known to infect humans (JCV, BKV, and SV40) is rarely helpful in establishing diagnosis of infection because of slow viral growth and the requirement for specialized cell lines (
52,
56). Serologic assays may be useful for retrospective epidemiological analysis, but they are of minimal use for diagnosis or therapeutic decisions because most overt polyomavirus infections are believed to result from reactivation of latent infections (
52,
56). Therefore, the use of modern molecular biology assays is an excellent and preferred alternative for the analysis of SV40 infections in the human population (
123). In addition, these sensitive and specific techniques are able to provide insights into the possible infectious etiology of human malignancies (
37,
79,
123).
FUTURE DIRECTIONS AND CONCLUSIONS
Mounting evidence indicates that SV40 is a human pathogen, and current molecular biology, pathology, and clinical data, taken together, show that SV40 is significantly associated with and may be functionally important in the development of some human malignancies. Now, prospective studies are needed to determine the prevalence of SV40 infections in different human populations and to assess how the virus is transmitted from person to person. Indeed, the Institute of Medicine recognized that this gap in our understanding of the pathogenesis of SV40 in humans is important and recommended “targeted biological research” of SV40 in humans, including “further study of the transmissibility of SV40 in humans” (
111). Considering that molecular biology approaches provide sensitive and specific approaches to analyze infectious diseases and malignancies with a possible infectious etiology, studies using these modern methods should be used to assess the distribution of SV40 infections and morbidity in humans today.
Although in vitro studies have established that SV40 disrupts critical cell cycle control pathways, it remains unknown whether these perturbations are sufficient for the virus to induce the development of malignancies in humans. Therefore, animal models that reproduce key features of SV40 infection and disease in humans are needed. Such models could provide precise evidence of the causal role of a particular pathway in SV40 pathogenesis in target tissues, allow further characterization of the molecular mechanisms of oncogenesis, and provide a preclinical system to test therapeutic interventions for these significant and increasingly common diseases.